×
Company
Overview
Management
Strategy
Contacts
Services
Overview
Advisory Boards
Clinical Trial Design
Consistent Research Guidelines
Continuing Medical Education Training
CRO Collaboration
Master Site Agreements
PK Facilities
Project Management
Site Selection
Subject Recruitment
Sponsor Agreements
Customization
Network
Map
View All Sites
Join Network
Trials
Current
Closed
Patients Resources
Sponsors
CME
Overview
Find / Register for a Course
Prevention and Therapies for Hepatitis and Chronic Liver Disease
IBS Series
The Effective Management of Ascites and Hepatorenal Syndrome
Improving Diagnostic and Treatment Outcomes for Cholestatic Liver Diseases and Pruritus
Our CME Partners
Continuing Education Credit Information
Exhibit and Sponsorship Opportunities
Patients
Contacts
Closed Trials
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients with Nonalcoholic Steatohepatitis (NASH) and fibrosis
Procurement of Blood Samples from Subjects with Diagnosed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) for Use in the Development of a Liver Fibrosis Test
Multicenter, Prospective Evaluation of the Beckman Coulter DxN HCV Viral Load Assay as an aid in the Management of HCV-Infected Individuals Undergoing Antiviral Therapy
Open-Label Study To Evaluate The Efficacy, Safety, Tolerability and Pharmacokinetics of MN-001 (tipelukast) on HDL (High Density Lipoprotein) Function and Serum Triglyceride Levels in Non-Alcoholic Steatohepatitis (NASH) Subjects with Hypertriglyceridemia.
Clinical Evaluation of the Xpert® HCV VL Assay
Multicenter, Prospective Evaluation of the Beckman Coulter DxN HBV Viral Load Assay as an Aid in the Management of HBV-Infected Individuals Undergoing Antiviral Therapy
A Multicenter, Double-Blind, Sponsor-Open Trial of IDN-6556 in Subjects Who had Hepatitis C Virus (HCV) Reinfection and Liver Fibrosis following Orthotopic Liver Transplantation for Chronic HCV Infection and Who Subsequently Achieved a Sustained Virologic Response Following anti-HCV Therapy
Pharmacokinetic and Pharmacodynamic Study of IDN-6556 in ACLF
Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cirrhosis (CLARITY)
Collection of Blood Specimens from Subjects Infected with Chronic Hepatitis C (Genotypes 2 and 3) and Treated with Sofosbuvir plus Ribavirin
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 (Champion2)
CTS-1027 in Interferon-Naive Hepatitis C Patients
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
Study of CTS-1027 in Hepatitis C Patients
Double-Blind, Placebo-Controlled Study of Two Doses of EPA-E in Patients With Non Alcoholic Steatohepatitis (NASH)
AST-120 Used to Treat Mild Hepatic Encephalopathy (ASTUTE)
Safety and Efficacy of AST-120 Compared to Lactulose in Patients With Hepatic Encephalopathy (AST015)
A Dose Ranging Study Of PF-00868554 In Combination With PEGASYS And COPEGUS In Patients With Chronic Hepatitis C Genotype 1 Infection
Retrospective Review of Baseline, On-Treatment, and Outcome Data for Patients in the United States Treated With Telaprevir After Marketing Approval
Safety & Efficacy of the Extracorporeal Liver Assist Device (ELAD) System in Patient With Hepatic Insufficiency
Safety and Efficacy of the Extracorporeal Liver Assist Device (ELAD®) In Patients With Fulminant Hepatic Failure (FHF)
Efficacy and Safety of the Extracorporeal Liver Assist Device (ELAD) in Acute on Chronic Hepatitis (SILVER)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2a Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Orally Administered TERN-101 Tablets in Adult Patients with Presumed Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH)
A Randomized Phase II Study of First Cycle Optimization for Regorafenib Treatment Compared to Standard Dose of Regorafenib in Patients with HCC Who Failed Any 1st Line Systemic Treatment and for Whom the Physician is Intending to Treat with Regorafenib, ReDOS HCC-21305
Top
